APA (7th ed.) Citation

HA, N., PJ, W., DP, W., Y, D., B, Y., S, Y., & A, C. (2021). Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: Exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. BMC psychiatry, 21(1), 492. https://doi.org/10.1186/s12888-021-03420-x

Chicago Style (17th ed.) Citation

HA, Nasrallah, Weiden PJ, Walling DP, Du Y, Yao B, Yagoda S, and Claxton A. "Aripiprazole Lauroxil 2-month Formulation with 1-day Initiation in Patients Hospitalized for an Acute Exacerbation of Schizophrenia: Exploratory Efficacy and Patient-reported Outcomes in the Randomized Controlled ALPINE Study." BMC Psychiatry 21, no. 1 (2021): 492. https://doi.org/10.1186/s12888-021-03420-x.

MLA (9th ed.) Citation

HA, Nasrallah, et al. "Aripiprazole Lauroxil 2-month Formulation with 1-day Initiation in Patients Hospitalized for an Acute Exacerbation of Schizophrenia: Exploratory Efficacy and Patient-reported Outcomes in the Randomized Controlled ALPINE Study." BMC Psychiatry, vol. 21, no. 1, 2021, p. 492, https://doi.org/10.1186/s12888-021-03420-x.